Large French study of over 23k patients with either PsA or PsO showed a longer persistence (time of initiation to discontinuation) in those who took IL-17i vs. TNFi for PsA and PsO pts. IL-17i longer than IL-12/23i in PsA pts. @RheumNow #EULAR2022 ABST#POS0075 https://t.co/rH1g4fPUYC

Gordon et al. Long term safety IL23i risankizumab in psoriatic disease. Overall rates are consistent with those expected for PsO/PsA populations. @RheumNow #EULAR2022 POS1023 https://t.co/yv5fFbUSI6

Does MTX have an impact on UST-immunogenicity in PsA? Post-hoc analysis from UST RCT in 110+ pts No difference in ADA rates & concentrations between MTX and non-MTX groups and ADA not associated w/ decreased UST levels POS0079 @RheumNow #EULAR2022 https://t.co/TA0YTx8qRT

2 year guselkumab data from Discover-2 @DrLauraCoates et al. Continue incremental improvements across all key domains through 2 years of treatment @RheumNow #EULAR2022 POS1017 https://t.co/wcSKCID9Yt

☄️ Biomarkers substudies of COSMOS & DISCOVER-1 RCT GUS in PsA: TNFi-IR pts have a different plasma signature w/ higher BL IL-22 & TNF *Association between BL IL-22 levels & W24 PASI75 and trend for BL IL-22 levels & W24 ACR20 #EULAR2022 @RheumNow POS0074 @StefanSiebert1 https://t.co/Midtug4NJO

All the domains of sexual sphere are deteriorated in RA and PsA. This aspect is often overlooked and can have a significant impact on pts QoL. It may be time to assess this aspect more specifically using CSFQ-14 and propose dedicated interventions. #OP0139 @RheumNow #EULAR2022 https://t.co/l0zyBIZ1LI

The GESPIC cohort reports in Axial PsA, 75% had inflammatory back pain, 45% met NY criteria for AS, 55% with active inflammatory change in SI joint and 60% in the spine. This is where the overlap between Axial PsA and Axial SpA happens, Kading et al #EULAR2022 @RheumNow OP0026

🚨 Study on MTX and male fertility Analysis of semen parameters in 🙋🏼‍♂️HC 🙋🏼‍♂️RA, PsA and PsO MTX naive 🙋🏼‍♂️Post MTX Reassuring data as NO significant effect of MTX was observed on several semen parameters. #EULAR2022 @RheumNow OP0131 https://t.co/Fq32lzAMAx

Rahman et al. Pooled safety data from IL23i guselkumab clinical trial programme in PsA. 1508 patients 2125 PY. No increase (and generally lower) than PBO. No IBD. @RheumNow #EULAR2022 POS1015 https://t.co/9otcpwW9ni

Rahman et al shows factors associated with variability of fatigue in PsA are systemic disease 34%, joint disease 16%, skin involvement 12%, accounting for 62% and leaving a residual effeect of 38% that was unexplained and needing further research #EULAR2022 @RheumNow OP0025 https://t.co/RoqjS64Xjy